Atlas Trials

University of Michigan Rogel Cancer Center

320 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch University of Michigan Rogel Cancer Center

RecordFirmDate
Tetrathiomolybdate in Hormone Refractory Prostate Cancer (NCT00150995)University of Michigan Rogel Cancer Center2001-05-01
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma (NCT00143871)University of Michigan Rogel Cancer Center2001-04-01
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma (NCT00176774)University of Michigan Rogel Cancer Center2001-02-01
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome (NCT00005598)University of Michigan Rogel Cancer Center2000-10-01
Radiation Therapy With Capecitabine in Rectal Cancer (NCT00176787)University of Michigan Rogel Cancer Center2000-10-01
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer (NCT00151034)University of Michigan Rogel Cancer Center2000-09-01
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer (NCT00900094)University of Michigan Rogel Cancer Center2000-06-01
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood (NCT00146055)University of Michigan Rogel Cancer Center2000-03-01
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood (NCT00143884)University of Michigan Rogel Cancer Center2000-03-01
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine (NCT00176761)University of Michigan Rogel Cancer Center2000-03-01
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder (NCT00136175)University of Michigan Rogel Cancer Center1999-11-01
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer (NCT00148070)University of Michigan Rogel Cancer Center1999-03-01
UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer (NCT00146042)University of Michigan Rogel Cancer Center1999-03-01
UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia (NCT00003598)University of Michigan Rogel Cancer Center1999-01-01
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate (NCT00151060)University of Michigan Rogel Cancer Center1998-12-01
Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma (NCT00230451)University of Michigan Rogel Cancer Center1997-11-01
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers (NCT00141765)University of Michigan Rogel Cancer Center1997-01-01
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus (NCT00003076)University of Michigan Rogel Cancer Center1995-10-01
Companion Pharmacogenetic Study to UMCC 9900/9901 (NCT00146029)University of Michigan Rogel Cancer Center
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (NCT02649530)University of Michigan Rogel Cancer Center
← Previous

Track University of Michigan Rogel Cancer Center automatically

Every clearance here is in the API, with alerts when new ones post.